Last updated 20 months ago
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
385 patients around the world
Available in Argentina, United States, Brazil, Spain
Kartos Therapeutics, Inc.
4Research sites
385Patients around the world
This study is for people with
Myeloproliferative syndromes
Myelofibrosis
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)High, intermediate-2, or intermediate-1 risk Dynamic International Prognostic System (DIPSS)Failure of prior treatment with JAK inhibitorECOG ≤ 2
- Prior splenectomySplenic irradiation within 3 months prior to randomizationHistory of major hemorrhage or intracranial hemorrhage within 6 months prior to randomizationHistory of stroke, reversible ischemic neurological defect or transient ischemic attack within 6 months prior to randomizationPrior MDM2 inhibitor therapy or p53-directed therapyPrior allogeneic stem-cell transplant or plans for allogeneic stem cell transplantHistory of major organ transplantGrade 2 or higher QTc prolongation (> 480 milliseconds per NCI-CTCAE criteria, version 5.0)
Sites
Sanatorio de la Mujer - Rosario
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Instituto Cardiovascular San Luis
Recruiting
Hospital Privado de Córdoba
Recruiting
StudyBOREAS
SponsorKartos Therapeutics, Inc.
Study typeInterventional
Conditions
Myelofibrosis
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT03662126
